The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome； Tuberous Sclerosis Complex； Dravet Syndrome； CDKL5； Neuronal ceroid lipofuscinoses (NCL)； febrile infection related epilepsy syndrome (FIRES)； Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
